Marc Banjak - Aug 14, 2024 Form 3 Insider Report for iBio, Inc. (IBIO)

Signature
/s/ Marc Banjak
Stock symbol
IBIO
Transactions as of
Aug 14, 2024
Transactions value $
$0
Form type
3
Date filed
8/14/2024, 05:24 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IBIO Common Stock (RSU) 1.88K Aug 14, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IBIO Stock Option (Right to Buy) Aug 14, 2024 Common Stock 800 $170.40 Direct F2
holding IBIO Stock Option (Right to Buy) Aug 14, 2024 Common Stock 600 $141.20 Direct F2
holding IBIO Stock Option (Right to Buy) Aug 14, 2024 Common Stock 3K $6.92 Direct F2
holding IBIO Stock Option (Right to Buy) Aug 14, 2024 Common Stock 29K $1.72 Direct F2
holding IBIO Stock Option (Right to Buy) Aug 14, 2024 Common Stock 55K $1.88 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of 1,875 shares of iBio, Inc. (the "Company") common stock, $0.001 par value per share (the "Common Stock") represented by 1,875 restricted stock units ("RSUs") granted under the Company's 2020 Omnibus Equity Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock. The 1,875 RSUs vested pro rata quarterly over 12 months and consists of 468 RSUs which fully vested on June 30, 2023, 469 RSUs which fully vested on September 30, 2023, 469 RSUs which fully vested on December 31, 2023 and 469 RSUs which fully vested on March 31, 2024.
F2 These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by the Company.
F3 These options vest in equal amounts on a quarterly basis over a 3-year period commencing on the date of grant, provided that the reporting person remains employed by the Company.